SCHEMBL8789232

SCHEMBL8789232

COc1ccc(CCN(C)CCCOc2ccc(N)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.66
HRH3 Q9Y5N1 2/20 0.56
AOC3 Q16853 2/20 0.54
SMPD1 P17405 6/20 0.51
SIGMAR1 Q99720 1/20 0.50
FDPS P14324 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
TAAR1 Q96RJ0 1/20 0.47
CACNA1F O60840 1/20 0.47
CHRM2 P08172 1/20 0.47
ACHE P22303 1/20 0.47
AGTR1 P30556 1/20 0.47
DRD3 P35462 1/20 0.47
CACNA1D Q01668 1/20 0.47
CACNA1S Q13698 1/20 0.47
CACNA1C Q13936 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8790478 0.93 KCNH2 (0.76) KCNH2HRH3AOC3SMPD1SIGMAR1
SCHEMBL8789557 0.89 AOC3 (0.66) KCNH2AOC3SMPD1SIGMAR1SLC6A2
SCHEMBL8790115 0.88 AOC3 (0.57) KCNH2AOC3SMPD1SIGMAR1SLC6A2
SCHEMBL7024969 0.86 KCNH2 (0.73) KCNH2HRH3AOC3SIGMAR1CACNA1F
SCHEMBL8789951 0.85 CYP3A4 (0.65) KCNH2AOC3SMPD1SLC6A4CACNA1F
SCHEMBL30354887 0.81 NPC1 (0.68) KCNH2AOC3TAAR1
SCHEMBL8789805 0.80 KCNH2 (0.83) KCNH2HRH3SIGMAR1ACHE
SCHEMBL8789857 0.79 TSHR (0.73) KCNH2HRH3ACHE
SCHEMBL8790447 0.79 AOC3 (0.53) AOC3SMPD1SIGMAR1TAAR1ACHE
SCHEMBL9160564 0.79 AOC3 (0.60) KCNH2AOC3SMPD1SIGMAR1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0569380-B1 ACRIDINE DERIVATIVES GLAXO LAB SA (FR) 1997-05-28 EP disclosed
US-5604237-A IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT LABORATOIRES GLAXO SA (FR) 1997-02-18 US disclosed
EP-0494623-A1 Acridine derivatives LABORATOIRES GLAXO SA (FR) 1992-07-15 EP disclosed